Research on HIV epidemiology and control. Covers prevention policy, HIV-substance use links, TB co-treatment, and clearing infection in newborns.
Researchers aim to evaluate the efficacy and cost-effectiveness of a peer-driven intervention to reach, test, and retain heterosexuals at high risk for HIV in their communities. The study will enroll 3400 participants over five years.
A team of Caltech biologists has developed a new, more potent HIV antibody that targets the virus's entry site. The antibody shows increased effectiveness against multiple subtypes of HIV, paving the way for potential clinical testing and improved vaccine development.
The UCSF Center for AIDS Prevention Studies will receive funding to tackle two primary goals of the National AIDS Strategy: increasing access to care and optimizing health outcomes. The program aims to close gaps in HIV testing, linkage to care, and treatment success among high-risk populations.
Recent research highlights that faster diagnostic tests are necessary but not sufficient to improve health outcomes for tuberculosis and HIV patients. The study emphasizes the need for thorough evaluation of diagnostics to ensure technical advancements translate into better patient care.
A new transdermal patch has been developed to deliver HIV medication over seven days, offering a more convenient and affordable option for patients. The patch shows significant potential in reducing the number of pills patients need to take daily, as well as decreasing shipping costs.
A French study found that non-targeted HIV rapid test screening in emergency departments identified only a few new cases, often at late stages and among patients in high-risk groups who had been tested previously. The study suggests that targeted HIV screening strategies may be more effective in controlling the epidemic.
A new study published in The New England Journal of Medicine found that the optimal time to integrate HIV treatment with TB therapy depends on a patient's immune status. Patients with advanced HIV disease who start antiretroviral treatment earlier show significant improvements in survival rates.
Starting HIV therapy two weeks after TB treatment increases survival by 33 percent, according to a recent study. The study suggests that immunosuppressed patients should be started on ART rapidly at two weeks after beginning TB therapy.
Researchers have discovered a highly effective antibody that can neutralize approximately 70% of globally circulating HIV strains by targeting the virus's envelope protein. The new findings suggest a promising target for AIDS vaccine development, with potential implications for broadening the protection against the fast-mutating virus.
A five-year HIV prevention initiative in India, Avahan, has successfully averted an estimated 100,000 infections. The program's effectiveness varied across states, with southern regions showing more significant reductions in HIV prevalence.
Over the past decade, antiretroviral therapy has effectively managed HIV in adults with virological failure to all three original drug classes. Since 2000, nearly one in five patients achieved undetectable viral loads after treatment failure, increasing to nearly three in five by 2009.
Researchers have discovered two genetically distinct HIV types in the cerebrospinal fluid of patients with HIV-associated dementia, which may predict disease progression and cognitive damage. The study found that one variant infects macrophages, a type of white blood cell, while the other reproduces in T cells.
Research suggests earlier male circumcision can reduce HIV and HPV transmission rates in South Africa. The study found that high prevalence of HPV among HIV-infected men and their female partners limits the effectiveness of male circumcision as a prevention method.
Home-based supervised oral HIV self-testing has been shown to be feasible in high-HIV-prevalence settings in urban Africa. The study found strong community readiness for this approach alongside other HIV counseling and testing strategies.
Researchers at UCLA have discovered how cell-penetrating peptides, such as the HIV TAT peptide, interact with cells to facilitate the transfer of molecular cargoes. The study reveals that these peptides can act like a Swiss Army Knife, interacting strongly with membranes and cytoskeletons to produce multiple pathways of translocation.
A study of nearly 3800 couples found that hormonal contraception increases a woman's chances of becoming infected with HIV-1. Women using injectable methods were twice as likely to transmit the virus to their male partner, emphasizing the need for alternative methods.
A University of Washington-led study found that using hormonal contraception increases an HIV-uninfected woman's chances of becoming infected by double. Women with HIV who use hormonal contraception are also twice as likely to transmit the virus to their male partners.
The VOICE trial will continue testing the safety and effectiveness of oral Truvada and tenofovir gel, while discontinuing daily use of oral tenofovir tablets. The trial enrolled 5,029 women across three countries to evaluate the efficacy of ARV-based approaches in preventing HIV transmission.
The MVA-B vaccine has been shown to induce an 90% immune response in humans against Human's immunodeficiency virus (HIV), with 85% of volunteers maintaining this response for at least one year. The vaccine works by training the immune system to recognize and respond to HIV particles and infected cells.
Researchers at Johns Hopkins have modified HIV to trigger an immune response, a major hurdle in vaccine development. The altered virus activates the adaptive immune system's response against HIV, negating its immunosuppressive properties.
Researchers from Boston University Schools of Medicine and Public Health are part of a $10 million grant to examine the consequences of alcohol on HIV disease. The study aims to understand how alcohol affects HIV clinical manifestations and develop more effective treatments.
Researchers used a new algorithm to predict human proteins that the HIV virus requires to replicate, offering potential new targets for controlling its spread. The study found many previously undiscovered proteins with high predictive value as prognostic markers.
Researchers have discovered a new class of compounds that stick to the sugary coating of the AIDS virus and inhibit its entry into cells. The synthetic lectins, developed from a compound called benzoboroxole, show promise as a potential microbicide to prevent HIV infection.
Researchers predict numerous human proteins required by HIV to replicate, discovering potential new targets for controlling the spread of HIV. The study also identifies prognostic markers to determine pathological outcome and AIDS development.
Researchers at Imperial College London discovered that removing cholesterol from HIV's membrane prevents the virus from damaging the immune system. This finding could lead to the development of an effective HIV vaccine by boosting the adaptive response and weakening the innate immune system's overreaction.
A $37 million grant has been awarded to test a combination prevention strategy to prevent HIV in African countries. The PopART project aims to reduce new HIV infections through community-wide testing, medical circumcision, and immediate ART for those testing positive.
A study from Lund University in Uganda found that almost one third of students have experienced sexual coercion, which is linked to risky sexual behavior. The researchers suggest targeting both perpetrators and victims to combat HIV in the country.
Researchers have demonstrated a new HIV vaccine approach by designing an altered form of the virus's outer coating protein. This allows for better targeting of immature B cell receptors, leading to enhanced immune responses in animal models.
New HIV cases linked to infected, medicated partners in gay community, suggesting a need for revised public health approach towards HIV counselling and education. The study reveals that existing HIV drug therapies can't prevent transmission from aware, medicated individuals.
Researchers studying HIV in Pakistan's general population found the virus has spread beyond at-risk groups to women and children. Genetic analysis suggests the strongest factor of disease spread is through men who sleep with male intravenous drug users.
Researchers have isolated 17 novel antibodies capable of neutralizing a broad spectrum of HIV variants, offering new targets for vaccine candidates. The potency of these antibodies is significantly higher than previously discovered ones, with some blocking infection up to 100 times more effectively.
A novel intervention strategy aims to provide HIV testing, medical care, and prevention services to this growing population. The YMSM of Color Initiative focuses on outreach, access to medical care, and preventing HIV transmission.
Deborah Anderson is leading a research study on plant-based antibodies to prevent HSV and HIV infections in women. The project aims to create affordable and large-capacity manufacturing systems for biopharmaceuticals, ensuring access to treatments for at-risk populations worldwide.
A NIH-led team has discovered a method to guide the evolution of powerful HIV-neutralizing antibodies, which could lead to the development of an effective vaccine. The researchers used deep sequencing and bioinformatics techniques to decipher the genetic data of immune cells that produce these antibodies.
Researchers found that HIV detection odds differ by method, with social networks and partner services outperforming alternative venue testing. The study suggests a multi-faceted approach to HIV prevention is needed, acknowledging individual differences within the demographic.
A USC scientist has created a lentiviral vector that targets and destroys HIV-infected cells using 'suicide gene therapy', depleting about 35% of existing HIV cells in culture dishes. The treatment approach is an important step towards curing HIV and will be tested in mice next.
A new study shows natural killer cells can contribute to HIV immune response, suggesting an additional cell type with anti-HIV activity. Researchers found that HIV strains infecting individuals with specific NK cell receptors had variant forms of viral proteins, implying the virus mutates to avoid NK cell activity.
A comprehensive review and data synthesis highlights the emergence of HIV epidemics among men who have sex with men in the region, with high rates of risky sexual behavior and concentrated epidemics in countries like Egypt and Sudan. The authors stress the need for expanded HIV surveillance and access to prevention and treatment services.
A new University of Cincinnati study found that missed opportunities for HIV diagnosis occur in 157 visits to an academic emergency department, 24 visits in an urban community hospital and six visits to a suburban community hospital.
Researchers at Caltech have developed a new, more potent form of the HIV-fighting protein cyanovirin-N by linking two proteins together. The engineered protein, called CVN2L0, is 18 times more effective at preventing infection than the naturally occurring single protein and neutralizes all 33 subtypes of HIV tested against it.
The study estimates that around 10 million injecting drug users globally are infected with HCV, while 1.3 million have HBV infection. The authors emphasize the need for increased attention to viral hepatitis in IDUs and enhanced access to treatments.
Researchers from BUSM and BMC will implement a clinical model to coordinate narcology and HIV systems of care in Russia, aiming to increase engagement in medical care among HIV-infected IDUs. The LINC project aims to address the missed opportunity of delayed or non-receipt of HIV medical care in Russia.
A global study of real-world circumcision rollout in South Africa found a marked reduction (>60 percent) of HIV acquisition among circumcised adult men. This is the first time such a large-scale community-level intervention has shown effectiveness in curbing HIV transmission.
Researchers focus on HIV cure research, highlighting the need for proactive outreach programs to prevent transmission in injecting drug users. The conference also emphasizes the importance of improving maternal and child health in sub-Saharan Africa and Southeast Asia.
The International AIDS Society will launch a Virtual Knowledge Centre to improve knowledge and strengthened operations research capacity for HIV/OST programmes in Eastern Europe and Central Asia. The centre aims to create an increased Russian-language evidence base around OST, harm reduction, and HIV.
The HPTN 052 study found that early initiation of combination antiretroviral therapy (cART) significantly reduces the risk of HIV transmission to uninfected partners, with a 96% reduction in transmissions. Early cART also benefits the infected individual by maintaining higher CD4 counts and reducing HIV-related illnesses or death.
Boston Medical Center has received a grant to expand its HIV/AIDS clinic and provide more comprehensive case management services. The new facility will enable collaboration between infectious diseases and primary care departments, improving the quality of care for patients with HIV/AIDS.
DNDi has launched a new programme to develop paediatric HIV treatments, focusing on improving dosing, tolerability and affordability. The initiative aims to fill the unmet treatment gap for millions of children with HIV/AIDS in low- and middle-income countries.
A large-scale study reveals that patients in Africa receiving cART for HIV can expect a near-normal lifespan, with females living longer than males. Early initiation of treatment is associated with longer life expectancy, highlighting the need for continued investment in HIV programming.
The Rome Statement for an HIV Cure aims to accelerate HIV cure research by building a global consensus on the state of HIV reservoirs and defining scientific priorities. The strategy recognizes the importance of developing a safe, accessible, and scalable HIV cure as a therapeutic and preventive strategy against HIV infection.
The success of antiretroviral-based HIV prevention, including pre-exposure prophylaxis and treatment for prevention, has transformed the landscape. Effective prevention strategies focus on implementation challenges such as HIV testing, mother-to-child transmission, and behavioural approaches.
The International AIDS Society advocates for an expanded global HIV strategy that incorporates 'Treatment as Prevention' to reduce transmission and prevent the onset of AIDS. This approach promotes widespread HIV testing and facilitated access to free treatment for all medically eligible individuals.
A new study published in The Lancet found that the number of sexual partners, rather than concurrent partnerships, is strongly predictive of HIV transmission in women. Researchers analyzed data from over 87,000 individuals in South Africa and found that men with multiple lifetime partners were more likely to transmit HIV.
The IAS and NIDA have awarded fellowships to young researchers from China and Indonesia to study the linkages between drug use and HIV. The fellowships will support research in clinical science, law, and public health to improve strategies targeting HIV infections related to drug use.
A new study led by Johns Hopkins researchers found that community members link adolescent girls' increased HIV vulnerability to weak structural support systems. The study's findings highlight the need for policies and interventions to strengthen cultural, economic, educational, and legal structures to protect girls.
The Gladstone Institutes will explore the molecular basis of HIV latency and develop inhibitors against cellular proteins to potentially cure HIV-infected patients. The funding is part of the National Institute of Allergy and Infectious Diseases' Martin Delaney Collaboratory initiative.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded over $14 million in grants to three research teams focused on developing strategies to eradicate HIV reservoirs. The grants aim to develop proteins that directly attack these reservoirs, as well as study immune cells' resistance to the virus.
The International AIDS Society announced six winners of prestigious scientific awards to be presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. These awards recognize innovative HIV research throughout the world, highlighting the challenges faced by women and girls in the epidemic.
A team of researchers led by UCSF and the Vaccine and Gene Therapy Institute aim to eradicate HIV from the body using a combination regimen. They will define HIV's reservoir, understand its creation and maintenance, and test potential treatments.
A new mathematical model predicts the location of mutations that lead to HIV-drug resistance, providing a potential solution to improve anti-HIV drug design. The study suggests that understanding these physical properties and interactions can help develop better strategies for combating the virus.